Categories: HealthcareNews

MaxCyte to Participate in Two Upcoming Investor Conferences

ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced Company management will participate at two upcoming investor conferences.

  • Stifel 2024 Healthcare Conference
    Fireside Chat on Monday, November 18th at 10:55 AM ET
  • Stephens Annual Investment Conference
    Fireside Chat on Tuesday, November 19th at 3:00 PM CT

A live and archived webcast of the event will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.

MaxCyte Contacts:

US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com

US Media Relations
Spectrum Science
Jordan Vines+1 540-629-3137
jvines@spectrumscience.com

Nominated Adviser and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500

UK IR Adviser
ICR Healthcare
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@icrhealthcare.com

Staff

Recent Posts

ScriptsMD Makes Semaglutide Weight Loss Treatment Accessible and Affordable

DELRAY BEACH, Fla., Nov. 4, 2024 /PRNewswire/ -- ScriptsMD is an innovative healthcare solution that…

2 hours ago

Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs

Vancouver, British Columbia--(Newsfile Corp. - November 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF)…

7 hours ago

SimBioSys Achieves Second FDA Clearance for TumorSight™ Viz and Introduces TumorSight™ Clinical Decision Support for Breast Cancer Surgery

CHICAGO, Nov. 4, 2024 /PRNewswire/ -- SimBioSys®, a pioneering TechBio company at the forefront of…

8 hours ago

GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

MENLO PARK, Calif., Nov. 4, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company…

8 hours ago

Becoming a Data-Driven Healthcare Organization: Info-Tech Releases New Blueprint for Maximizing Data Insights in a Complex Environment

As healthcare organizations confront the complexities of managing vast amounts of data, Info-Tech Research Group…

8 hours ago